{
      "Rank": 314,
      "Acronym": [
            "GIST"
      ],
      "AgreementOtherDetails": [
            "The sponsor can review results communications prior to public release and can embargo communications regarding trial results for up to 1 year (to first generate a multicenter publication) and a period that is 60 to 120 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication to delete confidential information, excluding the results of the Study."
      ],
      "AgreementPISponsorEmployee": [
            "No"
      ],
      "AgreementRestrictionType": [
            "OTHER"
      ],
      "AgreementRestrictiveAgreement": [
            "Yes"
      ],
      "ArmGroupDescription": [
            "Participants with KIT exon 11-mutant GIST.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B)."
      ],
      "ArmGroupInterventionName": [
            "Drug: Ponatinib",
            "Drug: Ponatinib"
      ],
      "ArmGroupLabel": [
            "Cohort A",
            "Cohort B"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "Female",
            "Male",
            "Hispanic or Latino",
            "Not Hispanic or Latino",
            "Unknown or Not Reported",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported"
      ],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01874665"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [
            "United States"
      ],
      "BaselineDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineDenomCountValue": [
            "30",
            "15",
            "45"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Total of all reporting groups"
      ],
      "BaselineGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineGroupTitle": [
            "Cohort A",
            "Cohort B",
            "Total"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation"
      ],
      "BaselineMeasureParamType": [
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Mean",
            "Mean"
      ],
      "BaselineMeasurePopulationDescription": [
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study."
      ],
      "BaselineMeasureTitle": [
            "Age, Continuous",
            "Sex: Female, Male",
            "Ethnicity (NIH/OMB)",
            "Race (NIH/OMB)",
            "Region of Enrollment",
            "Weight",
            "Height"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "years",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "kilogram (kg)",
            "centimeter (cm)"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [
            "10.37",
            "16.06",
            "12.63",
            "20.699",
            "13.917",
            "18.702",
            "7.839",
            "7.149",
            "7.534"
      ],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [
            "59.3",
            "53.9",
            "57.5",
            "11",
            "8",
            "19",
            "19",
            "7",
            "26",
            "1",
            "0",
            "1",
            "29",
            "15",
            "44",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "29",
            "15",
            "44",
            "0",
            "0",
            "0",
            "1",
            "0",
            "1",
            "30",
            "15",
            "45",
            "80.12",
            "75.10",
            "78.45",
            "171.20",
            "171.28",
            "171.23"
      ],
      "BaselinePopulationDescription": [
            "The intention to treat (ITT) population included all participants who received any dose of ponatinib in the study."
      ],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to evaluate the efficacy and safety of ponatinib in participants with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure of prior tyrosine kinase inhibitor (TKI) therapy."
      ],
      "BriefTitle": [
            "A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "July 31, 2016"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "GIST"
      ],
      "ConditionAncestorId": [
            "D000009372",
            "D000018204",
            "D000009370",
            "D000009369",
            "D000005770",
            "D000004067",
            "D000004066",
            "D000005767"
      ],
      "ConditionAncestorTerm": [
            "Neoplasms, Connective Tissue",
            "Neoplasms, Connective and Soft Tissue",
            "Neoplasms by Histologic Type",
            "Neoplasms",
            "Gastrointestinal Neoplasms",
            "Digestive System Neoplasms",
            "Digestive System Diseases",
            "Gastrointestinal Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC04",
            "BC06",
            "All",
            "BC17",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Neoplasms",
            "Digestive System Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Gastrointestinal Stromal Tumors",
            "Gastrointestinal Stromal Tumors"
      ],
      "ConditionBrowseLeafId": [
            "M24795",
            "M8038",
            "M6408",
            "M11469",
            "M19502",
            "M11467",
            "M8035",
            "M6407",
            "T2444"
      ],
      "ConditionBrowseLeafName": [
            "Gastrointestinal Stromal Tumors",
            "Gastrointestinal Neoplasms",
            "Digestive System Neoplasms",
            "Neoplasms, Connective Tissue",
            "Neoplasms, Connective and Soft Tissue",
            "Neoplasms by Histologic Type",
            "Gastrointestinal Diseases",
            "Digestive System Diseases",
            "Gastrointestinal Stromal Tumors"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000046152"
      ],
      "ConditionMeshTerm": [
            "Gastrointestinal Stromal Tumors"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "This is a non-randomized, open label, multi-center phase 2 study to evaluate the efficacy and safety of ponatinib in participants with metastatic and/or unresectable GIST after failure of prior TKI therapy. Participants whose tumors have an activating mutation in exon 11 of cellular KIT (KIT) will be enrolled into Cohort A. Participants whose tumors have other activating mutations will be enrolled into in Cohort B.\n\nThe primary objective is to assess clinical benefit in participants with KIT exon 11-mutant GIST (Cohort A) defined as clinical benefit rate (CBR), which is the composite of complete response (CR), partial response (PR) and stable disease (SD) lasting greater than or equal to (>=) 16 weeks per modified response evaluation criteria in solid tumors (RECIST 1.1) as a measure of disease control. The secondary objective is to assess clinical benefit in participants with GIST that lacks an activating KIT exon 11 mutation (Cohort B) and in the total participant population. The efficacy assessments are tumor response using RECIST Version 1.1, modified for GIST and assessment of progression-free survival (PFS) and overall survival (OS). The safety assessments include routine physical and laboratory evaluations, electrocardiograms (ECGs), echocardiograms (ECHOs), and adverse event (AE) monitoring. Other assessments include optional 18F fluorodeoxyglucose positron emission tomography (FDG-PET); optional pre- and post-treatment tumor biopsy for pharmacodynamic studies; and pharmacokinetics (PK). It is estimated that accrual will be complete within 1 year; the total estimated duration of the study is 3 years."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMale or female participants >=18 years old.\n\nGIST with failure of prior TKI therapy defined as:\n\nHistologically confirmed metastatic and/or unresectable GIST after experiencing failure of prior treatment with imatinib, sunitinib, and regorafenib. If prior TKI treatment was neoadjuvant therapy, then relapse must have occurred during the neoadjuvant therapy in order to consider it failed therapy.\nParticipants in Cohort A must have evidence of activation mutations in exon 11 of KIT in their tumors. Demonstration of an exon 11 mutation may be based on prior assessment or on evaluation of a tumor sample after enrollment in this study. Participants in Cohort B must have GIST that lacks activating mutations in KIT exon 11, but may have evidence of another activating mutation such as in KIT exon 9 or in PDGFR-\u03b1. Participants may be enrolled in the study prior to determination of the appropriate cohort (as long as both cohorts are open for enrollment).\nMeasurable disease per modified RECIST 1.1. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrollment.\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n\nAdequate hepatic function as defined by the following criteria:\n\nTotal serum bilirubin less than or equal to (<=) 1.5*Upper Limit of Normal (ULN), unless due to Gilbert's syndrome.\nALT <=2.5*ULN or <=5.0*ULN if liver metastases are present.\nAST <=2.5*ULN or <=5.0*ULN if liver metastases are present.\n\nAdequate renal function as defined by the following criterion:\n\na. Serum creatinine <1.5*ULN.\n\nAdequate pancreatic function as defined by the following criterion:\n\na. Serum lipase and amylase <=1.5*ULN.\n\nFor participants of childbearing potential, a negative pregnancy test must be documented prior to enrollment.\nFemale and male participants who are fertile must agree to use an effective form of contraception with their sexual partners from signing of the informed consent form for this study through 4 months after the end of treatment.\nProvision of written informed consent.\nWillingness and ability to comply with scheduled visits and study procedures\nFully recovered (<= Grade 1 or returned to baseline or deemed irreversible) from the acute effects of prior cancer therapy before initiation of study drug.\n\nExclusion Criteria:\n\nMajor surgery within 28 days prior to initiating therapy\nHistory of bleeding disorder\nHistory of acute pancreatitis within 1 year of study or history of chronic pancreatitis\nHistory of alcohol abuse\nUncontrolled hypertriglyceridemia (triglycerides >450 milligram per deciliter [mg/dL])\n\nClinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:\n\nAny history of myocardial infarction (MI).\nAny history of unstable angina.\nCongestive heart failure within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards within 6 months prior to enrollment.\nHistory of clinically significant (as determined by the treating physician) atrial arrhythmia.\nAny history of ventricular arrhythmia.\nAny history of cerebrovascular accident or transient ischemic attack (TIA).\nAny history of peripheral vascular infarction, including visceral infarction; or any revascularization procedure of any vasculature, including the placement of a stent.\nVenous thromboembolism including deep venous thrombosis (DVT) or pulmonary embolism within 6 months prior to enrollment.\nUncontrolled hypertension (diastolic blood pressure greater than (>) 90 millimeter of mercury [mmHg]; systolic >150 mmHg). Participants with hypertension should be under treatment on study entry to effect blood pressure control.\nTaking medications with a known risk of Torsades de Pointes.\nTaking any medications or herbal supplements that are known to be strong inhibitors of cytochrome P3A4 (CYP3A4) within at least 14 days before the first dose of ponatinib.\nOngoing or active infection. This includes but is not limited to the requirement for intravenous antibiotics.\nKnown history of human immunodeficiency virus (HIV). Testing is not required in the absence of prior documentation or known history.\nPregnant or breastfeeding.\nMalabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs.\nIndividuals with a history of a different malignancy, other than cervical cancer in situ, basal cell or squamous cell carcinoma of the skin, are ineligible, except if they have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy OR if the other primary malignancy is neither currently clinically significant nor requiring active intervention.\nUse of any approved TKIs or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is longer, prior to receiving study drug.\nAny condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with the evaluation of the drug."
      ],
      "EnrollmentCount": [
            "45"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "4",
            "2"
      ],
      "EventGroupDeathsNumAtRisk": [
            "30",
            "15"
      ],
      "EventGroupDescription": [
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily."
      ],
      "EventGroupId": [
            "EG000",
            "EG001"
      ],
      "EventGroupOtherNumAffected": [
            "30",
            "15"
      ],
      "EventGroupOtherNumAtRisk": [
            "30",
            "15"
      ],
      "EventGroupSeriousNumAffected": [
            "20",
            "6"
      ],
      "EventGroupSeriousNumAtRisk": [
            "30",
            "15"
      ],
      "EventGroupTitle": [
            "Cohort A",
            "Cohort B"
      ],
      "EventsDescription": [
            "At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment."
      ],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [
            "Treatment-emergent adverse events (TEAEs) are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (up to 3 years)"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowAchievementNumSubjects": [
            "30",
            "15",
            "0",
            "0",
            "30",
            "15"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [
            "Adverse Event",
            "Withdrawal by Subject",
            "Physician Decision",
            "Clinical Progressive Disease",
            "Study Terminated by Sponsor",
            "Documented Progressive Disease",
            "Other"
      ],
      "FlowGroupDescription": [
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 milligram (mg), taken orally once-daily.",
            "Participants with gastrointestinal stromal tumors (GIST) that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily."
      ],
      "FlowGroupId": [
            "FG000",
            "FG001"
      ],
      "FlowGroupTitle": [
            "Cohort A",
            "Cohort B"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowReasonNumSubjects": [
            "6",
            "2",
            "4",
            "1",
            "3",
            "0",
            "4",
            "3",
            "0",
            "2",
            "11",
            "7",
            "2",
            "0"
      ],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000970",
            "D000047428",
            "D000004791",
            "D000045504"
      ],
      "InterventionAncestorTerm": [
            "Antineoplastic Agents",
            "Protein Kinase Inhibitors",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action"
      ],
      "InterventionArmGroupLabel": [
            "Cohort A",
            "Cohort B"
      ],
      "InterventionBrowseBranchAbbrev": [
            "ANeo",
            "All",
            "AA"
      ],
      "InterventionBrowseBranchName": [
            "Antineoplastic Agents",
            "All Drugs and Chemicals",
            "Amino Acids"
      ],
      "InterventionBrowseLeafAsFound": [
            "Stable disease"
      ],
      "InterventionBrowseLeafId": [
            "M221142",
            "M24973",
            "T22"
      ],
      "InterventionBrowseLeafName": [
            "Ponatinib",
            "Protein Kinase Inhibitors",
            "Tyrosine"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Ponatinib 45 mg, tablets, orally, once-daily."
      ],
      "InterventionMeshId": [
            "C000545373"
      ],
      "InterventionMeshTerm": [
            "Ponatinib"
      ],
      "InterventionName": [
            "Ponatinib"
      ],
      "InterventionOtherName": [
            "AP24534",
            "Iclusig"
      ],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Gastrointestinal Neoplasms",
            "Gastrointestinal stromal tumor",
            "mesenchymal tumor"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 18, 2018"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "April 17, 2018"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Ariad Pharmaceuticals"
      ],
      "LimitationsAndCaveatsDescription": [
            "Study is ongoing. Uncontrolled Study. Small participant population. Non-randomized."
      ],
      "LocationCity": [
            "Boston",
            "Boston",
            "Portland",
            "Philadelphia"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "Massachusetts General Hospital, Site #047",
            "Dana-Farber Cancer Institute, Site #008",
            "Oregon Health & Sciences University, Site #048",
            "Fox Chase Cancer Center, Site #012"
      ],
      "LocationState": [
            "Massachusetts",
            "Massachusetts",
            "Oregon",
            "Pennsylvania"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "02114",
            "02215",
            "97239",
            "19111"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Following Failure of Prior Tyrosine Kinase Inhibitor Therapy"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Takeda"
      ],
      "OrgStudyId": [
            "AP24534-12-202"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment"
      ],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [
            "Blood and lymphatic system disorders",
            "Cardiac disorders",
            "Endocrine disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "Infections and infestations",
            "Infections and infestations",
            "Injury, poisoning and procedural complications",
            "Investigations",
            "Investigations",
            "Investigations",
            "Investigations",
            "Investigations",
            "Investigations",
            "Investigations",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Psychiatric disorders",
            "Renal and urinary disorders",
            "Reproductive system and breast disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Vascular disorders",
            "Blood and lymphatic system disorders",
            "Blood and lymphatic system disorders",
            "Blood and lymphatic system disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Injury, poisoning and procedural complications",
            "Injury, poisoning and procedural complications",
            "Injury, poisoning and procedural complications",
            "Injury, poisoning and procedural complications",
            "Injury, poisoning and procedural complications",
            "Injury, poisoning and procedural complications",
            "Injury, poisoning and procedural complications",
            "Investigations",
            "Investigations",
            "Investigations",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Psychiatric disorders",
            "Psychiatric disorders",
            "Psychiatric disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Reproductive system and breast disorders",
            "Reproductive system and breast disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Vascular disorders",
            "Vascular disorders",
            "Vascular disorders",
            "Eye disorders",
            "Eye disorders",
            "Eye disorders",
            "Eye disorders",
            "Eye disorders",
            "Eye disorders",
            "Eye disorders",
            "Eye disorders",
            "Eye disorders",
            "Eye disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Ear and labyrinth disorders",
            "Ear and labyrinth disorders",
            "Ear and labyrinth disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders",
            "General disorders"
      ],
      "OtherEventSourceVocabulary": [
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)"
      ],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "OtherEventStatsNumAffected": [
            "1",
            "5",
            "1",
            "2",
            "3",
            "1",
            "14",
            "6",
            "3",
            "1",
            "14",
            "5",
            "8",
            "2",
            "3",
            "1",
            "4",
            "4",
            "6",
            "3",
            "1",
            "2",
            "7",
            "2",
            "3",
            "1",
            "15",
            "9",
            "3",
            "1",
            "13",
            "3",
            "2",
            "1",
            "7",
            "3",
            "0",
            "2",
            "1",
            "3",
            "2",
            "1",
            "3",
            "5",
            "1",
            "2",
            "5",
            "5",
            "7",
            "6",
            "1",
            "2",
            "3",
            "4",
            "6",
            "1",
            "11",
            "4",
            "5",
            "1",
            "3",
            "3",
            "2",
            "2",
            "3",
            "4",
            "7",
            "0",
            "3",
            "0",
            "5",
            "2",
            "15",
            "3",
            "3",
            "0",
            "4",
            "0",
            "1",
            "1",
            "3",
            "2",
            "13",
            "7",
            "4",
            "0",
            "4",
            "1",
            "1",
            "2",
            "3",
            "0",
            "8",
            "4",
            "3",
            "4",
            "4",
            "0",
            "3",
            "1",
            "2",
            "2",
            "2",
            "2",
            "11",
            "4",
            "0",
            "3",
            "2",
            "1",
            "1",
            "3",
            "15",
            "12",
            "15",
            "2",
            "2",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "1",
            "0",
            "2",
            "0",
            "2",
            "0",
            "2",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "2",
            "0",
            "1",
            "1",
            "2",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "0",
            "2",
            "2",
            "0",
            "0",
            "2",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "2",
            "2",
            "0",
            "0",
            "2",
            "1",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "2",
            "0",
            "2",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "2",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "2",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "2",
            "1",
            "0",
            "1",
            "0",
            "0",
            "2",
            "2",
            "0",
            "2",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "2",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0"
      ],
      "OtherEventStatsNumAtRisk": [
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15"
      ],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [
            "ANAEMIA",
            "ATRIAL FIBRILLATION",
            "HYPOTHYROIDISM",
            "ABDOMINAL PAIN",
            "ASCITES",
            "CONSTIPATION",
            "DIARRHOEA",
            "DRY MOUTH",
            "DYSPEPSIA",
            "NAUSEA",
            "STOMATITIS",
            "VOMITING",
            "CHILLS",
            "FATIGUE",
            "NON-CARDIAC CHEST PAIN",
            "OEDEMA PERIPHERAL",
            "PAIN",
            "PYREXIA",
            "PNEUMONIA",
            "URINARY TRACT INFECTION",
            "FALL",
            "ALANINE AMINOTRANSFERASE INCREASED",
            "AMYLASE INCREASED",
            "ASPARTATE AMINOTRANSFERASE INCREASED",
            "BLOOD ALKALINE PHOSPHATASE INCREASED",
            "EJECTION FRACTION DECREASED",
            "LIPASE INCREASED",
            "WEIGHT DECREASED",
            "DECREASED APPETITE",
            "DEHYDRATION",
            "HYPERGLYCAEMIA",
            "HYPOPHOSPHATAEMIA",
            "ARTHRALGIA",
            "BACK PAIN",
            "BONE PAIN",
            "MUSCLE SPASMS",
            "MYALGIA",
            "NECK PAIN",
            "PAIN IN EXTREMITY",
            "TUMOUR HAEMORRHAGE",
            "DIZZINESS",
            "HEADACHE",
            "PERIPHERAL SENSORY NEUROPATHY",
            "INSOMNIA",
            "URINARY RETENTION",
            "ERECTILE DYSFUNCTION",
            "COUGH",
            "DYSPHONIA",
            "DYSPNOEA",
            "NASAL CONGESTION",
            "PLEURAL EFFUSION",
            "ALOPECIA",
            "DRY SKIN",
            "HYPERHIDROSIS",
            "PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME",
            "PRURITUS",
            "RASH",
            "HYPERTENSION",
            "LEUKOCYTOSIS",
            "IRON DEFICIENCY ANAEMIA",
            "LYMPH NODE PAIN",
            "SINUS TACHYCARDIA",
            "PERICARDIAL EFFUSION",
            "SINUS BRADYCARDIA",
            "ABDOMINAL DISCOMFORT",
            "ABDOMINAL DISTENSION",
            "GASTROOESOPHAGEAL REFLUX DISEASE",
            "ABDOMINAL TENDERNESS",
            "COLITIS",
            "DYSPHAGIA",
            "ERUCTATION",
            "GASTRIC ULCER",
            "HAEMORRHOIDS",
            "OBSTRUCTION GASTRIC",
            "OESOPHAGEAL PAIN",
            "PROCTALGIA",
            "TOOTHACHE",
            "UPPER GASTROINTESTINAL HAEMORRHAGE",
            "CELLULITIS",
            "CLOSTRIDIUM DIFFICILE INFECTION",
            "CYSTITIS",
            "DIVERTICULITIS",
            "INFECTION",
            "ORAL CANDIDIASIS",
            "ORAL INFECTION",
            "OTITIS MEDIA",
            "POSTOPERATIVE WOUND INFECTION",
            "PYURIA",
            "SKIN INFECTION",
            "TOOTH INFECTION",
            "UPPER RESPIRATORY TRACT INFECTION",
            "HEAD INJURY",
            "HIP FRACTURE",
            "INCISION SITE HAEMATOMA",
            "LOWER LIMB FRACTURE",
            "POST PROCEDURAL HAEMORRHAGE",
            "PROCEDURAL HYPOTENSION",
            "PROCEDURAL PAIN",
            "PLATELET COUNT DECREASED",
            "BLOOD BILIRUBIN INCREASED",
            "BLOOD CREATININE INCREASED",
            "FLANK PAIN",
            "GROIN PAIN",
            "LIMB DISCOMFORT",
            "MUSCULOSKELETAL PAIN",
            "MUSCULOSKELETAL CHEST PAIN",
            "MUSCULOSKELETAL DISCOMFORT",
            "NUCHAL RIGIDITY",
            "OSTEOARTHRITIS",
            "PAIN IN JAW",
            "ROTATOR CUFF SYNDROME",
            "MALIGNANT PLEURAL EFFUSION",
            "DYSGEUSIA",
            "MEMORY IMPAIRMENT",
            "TREMOR",
            "CEREBROVASCULAR ACCIDENT",
            "DIZZINESS POSTURAL",
            "DYSAESTHESIA",
            "HYPERAESTHESIA",
            "LETHARGY",
            "PERIPHERAL MOTOR NEUROPATHY",
            "RESTLESS LEGS SYNDROME",
            "SOMNOLENCE",
            "ANXIETY",
            "CONFUSIONAL STATE",
            "DEPRESSION",
            "POLLAKIURIA",
            "ACUTE KIDNEY INJURY",
            "DYSURIA",
            "MICTURITION URGENCY",
            "HAEMATURIA",
            "NOCTURIA",
            "URINARY TRACT OBSTRUCTION",
            "URINARY TRACT PAIN",
            "GYNAECOMASTIA",
            "TESTICULAR PAIN",
            "DYSPNOEA EXERTIONAL",
            "WHEEZING",
            "EPISTAXIS",
            "HYPOXIA",
            "OROPHARYNGEAL PAIN",
            "PLEURITIC PAIN",
            "PULMONARY OEDEMA",
            "THROAT IRRITATION",
            "UPPER-AIRWAY COUGH SYNDROME",
            "DERMATITIS ACNEIFORM",
            "EXFOLIATIVE RASH",
            "NIGHT SWEATS",
            "PAIN OF SKIN",
            "PITYRIASIS RUBRA PILARIS",
            "PRURITUS GENERALISED",
            "RASH FOLLICULAR",
            "RASH PRURITIC",
            "SKIN REACTION",
            "FLUSHING",
            "HOT FLUSH",
            "PERIPHERAL ARTERY STENOSIS",
            "VISION BLURRED",
            "DIPLOPIA",
            "DRY EYE",
            "EPISCLERITIS",
            "EYELID PAIN",
            "HYPERMETROPIA",
            "PERIORBITAL OEDEMA",
            "VISUAL ACUITY REDUCED",
            "VISUAL IMPAIRMENT",
            "VITREOUS DETACHMENT",
            "HYPOGLYCAEMIA",
            "HYPOKALAEMIA",
            "HYPONATRAEMIA",
            "HYPERKALAEMIA",
            "HYPERNATRAEMIA",
            "HYPERTRIGLYCERIDAEMIA",
            "HYPOCALCAEMIA",
            "HYPOMAGNESAEMIA",
            "IRON DEFICIENCY",
            "EAR DISCOMFORT",
            "EAR PAIN",
            "HYPOACUSIS",
            "EARLY SATIETY",
            "ASTHENIA",
            "CHEST PAIN",
            "FACE OEDEMA",
            "FEELING OF BODY TEMPERATURE CHANGE",
            "MALAISE",
            "PERIPHERAL SWELLING"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [
            "Hypertension",
            "Procedural hypotension",
            "Pyrexia",
            "Chills",
            "Feeling of body temperature change",
            "Albumin decreased",
            "Alkaline phosphatase increased",
            "Alanine aminotransferase (ALT) increased",
            "Amylase",
            "Absolute neutrophil count (ANC) decreased",
            "Aspartate aminotransferase (AST) increased",
            "Bicarbonate decreased",
            "Bilirubin",
            "Calcium decreased",
            "Calcium increased",
            "Creatinine increased",
            "Glucose decreased",
            "Glucose increased",
            "Hemoglobin decreased",
            "Lipase increased",
            "Lymphocytes (ALC)/ lymphopenia",
            "Phosphorus decreased",
            "Platelets decreased",
            "Potassium decreased",
            "Potassium increased",
            "Sodium decreased",
            "Sodium increased",
            "Triglycerides increased",
            "White blood cells (WBC) decreased",
            "Ejection Fraction Decreased",
            "Atrial Fibrillation",
            "Sinus Tachycardia",
            "Cardiac Failure Congestive",
            "Myocardial Ischaemia",
            "Pericardial Effusion",
            "Right Ventricular Dysfunction",
            "Sinus Bradycardia",
            "Congestive Cardiac Failure",
            "Right Ventricular Dysfunction",
            "Decreased Ejection Fraction",
            "Pulmonary Oedema",
            "TEAE",
            "SAE"
      ],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeDenomCountValue": [
            "28",
            "15",
            "30",
            "15",
            "28",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "0",
            "0"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily.",
            "Participants with KIT exon 11-mutant GIST ponatinib: 45 mg, taken orally once-daily.",
            "Participants with GIST that lack KIT exon 11 mutations (Cohort B) ponatinib: 45 mg, taken orally once-daily."
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeGroupTitle": [
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B",
            "Cohort A",
            "Cohort B"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "To assess clinical benefit rate in participants with KIT exon 11-mutant GIST.It is defined as the composite of complete response(CR),partial response(PR),and stable disease(SD) lasting >=16 weeks per modified Response Evaluation Criteria In Solid Tumors(RECIST) 1.1 as a measure of disease control.CR is complete disappearance of all target lesions and non-target disease, with the exception of nodal disease.All nodes, both target and non-target, must decrease to normal (short axis <10millimeter [mm]).No new lesions.PR is >=30% decrease under baseline of the sum of diameters of all target lesions.The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions.No unequivocal progression of non-target disease.No new lesions.SD is not qualifying for CR,PR,Progressive Disease(PD).PD is >=20% increase from the smallest prior sum of the longest diameter(SLD)and with >=5mm absolute increase, or appearance of a new lesion.",
            "To assess clinical benefit rate in participants with GIST that lacks KIT exon 11 mutations (Cohort B) and in the total participant population. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis <10 millimeter [mm]). No new lesions. PR was defined as >=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as not qualifying for CR, PR, PD.",
            "PFS is defined as the duration of time from start of study drug administration to time of objective disease progression or death due to any cause, whichever may come first. To assess PFS in each cohort and in the total participant population.",
            "ORR is defined as the composite of CR and PR per Response Evaluation Criteria in RECIST 1.1, assessed for each cohort and in the total participant population. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). No new lesions. PR was defined as >=30% decrease under baseline of the sum of diameters of all target lesions.",
            "OS is defined as the time interval between the first dose of study drug to death due to any cause. Overall survival was analyzed using the Kaplan-Meier method."
      ],
      "OutcomeMeasureDispersionType": [
            "95% Confidence Interval",
            "95% Confidence Interval",
            "95% Confidence Interval",
            "95% Confidence Interval",
            "95% Confidence Interval"
      ],
      "OutcomeMeasureParamType": [
            "Number",
            "Number",
            "Median",
            "Number",
            "Median",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants"
      ],
      "OutcomeMeasurePopulationDescription": [
            "The ITT population included all participants who received any dose of ponatinib in the study. The ITT population where data at specified time points was available.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study. The ITT population where data at specified time points was available.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "The ITT population included all participants who received any dose of ponatinib in the study.",
            "Data was not collected for Cmax,ss, since outcome measure was not planned to be analyzed."
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "16 weeks after first dose",
            "16 weeks after first dose",
            "From date of enrollment until the end of the study or disease progression or death due to any cause, whichever came first, assessed up to 3 years",
            "From date of enrollment until discontinuation or the end of the study, whichever came first, assessed up to 3 years",
            "From first dose of drug until the end of the study or death, whichever came first, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "Pre-dose and at multiple timepoints (up to 1 month) post-dose"
      ],
      "OutcomeMeasureTitle": [
            "Clinical Benefit Rate (CBR) in Cohort A",
            "Clinical Benefit Rate (CBR) in Cohort B",
            "Progression-free Survival (PFS)",
            "Percentage of Participants With Objective Response Rate (ORR)",
            "Overall Survival (OS)",
            "Number of Participants With Physical Examination",
            "Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Sign Measurements",
            "Number of Participants With Worst Shift From Baseline Values to Post-baseline Values in Laboratory Parameters",
            "Number of Participants With TEAEs Related to Electrocardiogram (ECG) Findings",
            "Number of Participants With TEAEs Related to Echocardiography Parameter",
            "Number of Participants Reporting One or More TEAEs and Serious Adverse Event (SAE)",
            "Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "percentage (%) of participants",
            "percentage (%) of participants",
            "days",
            "percentage of participants",
            "days",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeMeasurementComment": [
            "Upper limit of confidence interval was not estimable."
      ],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeMeasurementLowerLimit": [
            "18.6",
            "4.3",
            "57.0",
            "55.0",
            "0.9",
            "0.0",
            "234.0",
            "90.0"
      ],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [
            "55.9",
            "48.1",
            "252.0",
            "502.0",
            "23.5",
            "21.8",
            "836.0",
            "NA"
      ],
      "OutcomeMeasurementValue": [
            "35.7",
            "20.0",
            "112.0",
            "57.0",
            "7.1",
            "0.0",
            "411.0",
            "399.0",
            "6",
            "1",
            "15",
            "2",
            "1",
            "0",
            "7",
            "3",
            "3",
            "1",
            "1",
            "0",
            "13",
            "4",
            "12",
            "8",
            "11",
            "7",
            "3",
            "5",
            "2",
            "0",
            "11",
            "8",
            "1",
            "1",
            "4",
            "2",
            "5",
            "4",
            "5",
            "1",
            "3",
            "3",
            "1",
            "3",
            "19",
            "9",
            "10",
            "5",
            "6",
            "7",
            "5",
            "4",
            "5",
            "1",
            "2",
            "0",
            "5",
            "2",
            "8",
            "3",
            "8",
            "1",
            "7",
            "2",
            "2",
            "0",
            "2",
            "0",
            "1",
            "2",
            "1",
            "2",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "2",
            "0",
            "1",
            "30",
            "15",
            "20",
            "6"
      ],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [
            "globaloncologymedinfo@takeda.com"
      ],
      "PointOfContactOrganization": [
            "Ariad Pharmaceuticals"
      ],
      "PointOfContactPhone": [
            "+1-844-662-8532"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Medical Director"
      ],
      "PrimaryCompletionDate": [
            "February 28, 2015"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "To assess clinical benefit rate in participants with KIT exon 11-mutant GIST.It is defined as the composite of complete response(CR),partial response(PR),and stable disease(SD) lasting >=16 weeks per modified Response Evaluation Criteria In Solid Tumors(RECIST) 1.1 as a measure of disease control.CR is complete disappearance of all target lesions and non-target disease, with the exception of nodal disease.All nodes, both target and non-target, must decrease to normal (short axis <10millimeter [mm]).No new lesions.PR is >=30% decrease under baseline of the sum of diameters of all target lesions.The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions.No unequivocal progression of non-target disease.No new lesions.SD is not qualifying for CR,PR,Progressive Disease(PD).PD is >=20% increase from the smallest prior sum of the longest diameter(SLD)and with >=5mm absolute increase, or appearance of a new lesion."
      ],
      "PrimaryOutcomeMeasure": [
            "Clinical Benefit Rate (CBR) in Cohort A"
      ],
      "PrimaryOutcomeTimeFrame": [
            "16 weeks after first dose"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [
            "May 17, 2016"
      ],
      "ResultsFirstPostDateType": [
            "Estimate"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "March 14, 2016"
      ],
      "ResultsFirstSubmitQCDate": [
            "April 11, 2016"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "To assess clinical benefit rate in participants with GIST that lacks KIT exon 11 mutations (Cohort B) and in the total participant population. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis <10 millimeter [mm]). No new lesions. PR was defined as >=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as not qualifying for CR, PR, PD.",
            "PFS is defined as the duration of time from start of study drug administration to time of objective disease progression or death due to any cause, whichever may come first. To assess PFS in each cohort and in the total participant population.",
            "ORR is defined as the composite of CR and PR per Response Evaluation Criteria in RECIST 1.1, assessed for each cohort and in the total participant population. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). No new lesions. PR was defined as >=30% decrease under baseline of the sum of diameters of all target lesions.",
            "OS is defined as the time interval between the first dose of study drug to death due to any cause. Overall survival was analyzed using the Kaplan-Meier method."
      ],
      "SecondaryOutcomeMeasure": [
            "Clinical Benefit Rate (CBR) in Cohort B",
            "Progression-free Survival (PFS)",
            "Percentage of Participants With Objective Response Rate (ORR)",
            "Overall Survival (OS)",
            "Number of Participants With Physical Examination",
            "Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Sign Measurements",
            "Number of Participants With Worst Shift From Baseline Values to Post-baseline Values in Laboratory Parameters",
            "Number of Participants With TEAEs Related to Electrocardiogram (ECG) Findings",
            "Number of Participants With TEAEs Related to Echocardiography Parameter",
            "Number of Participants Reporting One or More TEAEs and Serious Adverse Event (SAE)",
            "Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib"
      ],
      "SecondaryOutcomeTimeFrame": [
            "16 weeks after first dose",
            "From date of enrollment until the end of the study or disease progression or death due to any cause, whichever came first, assessed up to 3 years",
            "From date of enrollment until discontinuation or the end of the study, whichever came first, assessed up to 3 years",
            "From first dose of drug until the end of the study or death, whichever came first, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "From date of enrollment until the End-of-Treatment, assessed up to 3 years",
            "Pre-dose and at multiple timepoints (up to 1 month) post-dose"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment"
      ],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [
            "Blood and lymphatic system disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "General disorders",
            "Hepatobiliary disorders",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Infections and infestations",
            "Injury, poisoning and procedural complications",
            "Metabolism and nutrition disorders",
            "Metabolism and nutrition disorders",
            "Musculoskeletal and connective tissue disorders",
            "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "Nervous system disorders",
            "Nervous system disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Vascular disorders",
            "Vascular disorders",
            "Cardiac disorders",
            "Nervous system disorders"
      ],
      "SeriousEventSourceVocabulary": [
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)",
            "MedDRA (19.0)"
      ],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "SeriousEventStatsNumAffected": [
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "3",
            "1",
            "1",
            "0",
            "2",
            "0",
            "1",
            "0",
            "3",
            "0",
            "1",
            "0",
            "0",
            "1",
            "2",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "3",
            "0",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "3",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0"
      ],
      "SeriousEventStatsNumAtRisk": [
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15",
            "30",
            "15"
      ],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [
            "ANAEMIA",
            "ATRIAL FIBRILLATION",
            "MYOCARDIAL ISCHAEMIA",
            "RIGHT VENTRICULAR DYSFUNCTION",
            "ABDOMINAL PAIN",
            "DUODENAL STENOSIS",
            "NAUSEA",
            "OBSTRUCTION GASTRIC",
            "SMALL INTESTINAL OBSTRUCTION",
            "SMALL INTESTINAL ULCER PERFORATION",
            "UPPER GASTROINTESTINAL HAEMORRHAGE",
            "VOMITING",
            "FATIGUE",
            "HEPATIC FAILURE",
            "COLONIC ABSCESS",
            "PNEUMONIA",
            "SEPSIS",
            "URINARY TRACT INFECTION",
            "HIP FRACTURE",
            "DEHYDRATION",
            "HYPERCALCAEMIA",
            "MUSCULAR WEAKNESS",
            "NEOPLASM PROGRESSION",
            "TUMOUR HAEMORRHAGE",
            "CEREBROVASCULAR ACCIDENT",
            "SYNCOPE",
            "ACUTE RESPIRATORY FAILURE",
            "DYSPNOEA",
            "HYPOXIA",
            "PULMONARY EMBOLISM",
            "RESPIRATORY FAILURE",
            "DEEP VEIN THROMBOSIS",
            "PERIPHERAL ARTERY STENOSIS",
            "CARDIAC FAILURE CONGESTIVE",
            "SPINAL CORD COMPRESSION"
      ],
      "StartDate": [
            "June 5, 2013"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "April 2018"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 11, 2013"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "May 29, 2013"
      ],
      "StudyFirstSubmitQCDate": [
            "June 7, 2013"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}